Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

T. Heffernan · SciRah

Researcher profile · Semantic Scholar

T. Heffernan

Share profile

T. Heffernan — researcher profile on SciRah

h-index: 50
Works: 209
Citations: 17K

Most-cited papers

Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials
T. Yap, N. Daver, Mikhila Mahendra, Ji-Xiang Zhang +45 more
2023Nature Medicine359 citations Open access
Semantic Scholar
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, Zi-Yue Li +51 more
2024Cancer Discovery227 citations
Semantic Scholar
Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis
Edoardo Del Poggetto, Iwt Ho, C. Balestrieri, Er-Yen Yen +29 more
2021Science218 citations Open access
Semantic Scholar
KRASG12D inhibition reprograms the tumor microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells
K. Mahadevan, K. McAndrews, V. LeBleu, Su-Juan Yang +20 more
2023Cancer Cell191 citations Open access
Semantic Scholar
Oxidative Phosphorylation is a Metabolic Vulnerability in Chemotherapy Resistant Triple Negative Breast Cancer
K. Evans, E. Yuca, Stephen S Scott, Ming Zhao +22 more
2021Cancer Research130 citations Open access
Semantic Scholar
Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis
Michael P. Kim, Xin-Qun Li, Jenying Deng, Yun Zhang +18 more
2021Cancer Discovery116 citations Open access
Semantic Scholar
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
C. Vellano, Michael G. White, M. Andrews, M. Chelvanambi +61 more
2022Nature96 citations Open access
Semantic Scholar
PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma
V. Giuliani, Meredith A. Miller, Chiu-Yi Liu, Stella R. Hartono +34 more
2021Nature Communications60 citations Open access
Semantic Scholar
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lyu, Sabine Jurado, K. Kostyrko +34 more
2024Nature Cancer56 citations Open access
Semantic Scholar
Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma
A. Osman, E. Arslan, Mason D. Bartels, C. Michikawa +15 more
2023Clinical Cancer Research46 citations Open access
Semantic Scholar
Loss of ARID1A promotes epithelial-mesenchymal transition and sensitizes pancreatic tumors to proteotoxic stress
Hideo Tomihara, F. Carbone, L. Perelli, Justin K. Huang +18 more
2020Cancer Research46 citations Open access
Semantic Scholar
Targeting glucose metabolism sensitizes pancreatic cancer to MEK inhibition
Liang Yan, Bo Tu, Jun Yao, Jing Gong +13 more
2021Cancer Research42 citations Open access
Semantic Scholar
Evolutionary fingerprints of epithelial-to-mesenchymal transition
L. Perelli, Li Zhang, Sarah Mangiameli, Francesca Giannese +32 more
2025Nature41 citations Open access
Semantic Scholar
Sequential administration of XPO1 and ATR inhibitors enhances therapeutic response in TP53-mutated colorectal cancer
A. Inoue, Frederick S. Robinson, R. Minelli, Hideo Tomihara +31 more
2021Gastroenterology38 citations Open access
Semantic Scholar
p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.
A. Carugo, R. Minelli, Luigi Sapio, M. Soeung +32 more
2026Cancer Cell36 citations
Semantic Scholar
Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints
J. Molkentine, D. Molkentine, K. Bridges, T. Xie +12 more
2020International Journal of Radiation Biology36 citations Open access
Semantic Scholar
Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function
Manish Kumar, D. Molkentine, J. Molkentine, K. Bridges +19 more
2021Nature Communications33 citations Open access
Semantic Scholar
Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer
L. Perelli, F. Carbone, Li Zhang, Justin K. Huang +40 more
2023Nature Cancer30 citations Open access
Semantic Scholar
Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies
Daniel D. Shapiro, M. Soeung, L. Perelli, Eleonora Dondossola +21 more
2021Cancers26 citations Open access
Semantic Scholar
SMARCB1 regulates the hypoxic stress response in sickle cell trait
M. Soeung, L. Perelli, Ziheng Chen, Eleonora Dondossola +25 more
2023Proceedings of the National Academy of Sciences of the United States of America25 citations Open access
Semantic Scholar
Abstract 1091: BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan
D. Gerlach, M. Gmachl, J. Ramharter, Jessica L. F. Teh +17 more
2020Tumor Biology24 citations
Semantic Scholar
Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lu, S. Jurado, K. Kostyrko +24 more
2023bioRxiv22 citations Open access
Semantic Scholar
Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.
M. H. Hofmann, Hengyu Lu, Ulrich Duenzinger, D. Gerlach +13 more
2021Clinical Trials19 citations
Semantic Scholar
Discovery of IACS-9439, a potent, exquisitely selective and orally bioavailable inhibitor of CSF1R.
B. Czako, J. Marszalek, Jason P. Burke, P. Mandal +23 more
2020Journal of Medicinal Chemistry19 citations Open access
Semantic Scholar
First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors.
T. Yap, E. Dumbrava, Jordi Rodon Ahnert, D. Hong +16 more
202115 citations
Semantic Scholar
An Allele Agnostic Mutant KRAS Inhibitor Suppresses Tumor Maintenance Signals and Reprograms Tumor Immunity in Pancreatic Cancer
K. McAndrews, Francesca Paradiso, Clint A. Stalnecker, Benson S Chellakkan +41 more
2025Science Translational Medicine14 citations
Semantic Scholar
Abstract 3317: KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harbouring KRASG12V mutations and KRAS wild-type amplifications
Antonio Tedeschi, David H. Peng, Fiorella Schischlik, Lorenz Herdeis +35 more
2024Cancer Research13 citations
Semantic Scholar
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy
Daniel D. Shapiro, N. Zacharias, D. Tripathi, Menuka Karki +17 more
2023Clinical and Translational Medicine12 citations Open access
Semantic Scholar
The cytosolic iron–sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors
Abena B. Redwood, Xiao-Mei Zhang, S. Seth, Zhong-Qi Ge +5 more
2021npj Breast Cancer12 citations Open access
Semantic Scholar
Oncogenic KrasG12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8+ T cells dependent manner
K. Mahadevan, K. McAndrews, V. LeBleu, Su-Juan Yang +18 more
2023bioRxiv11 citations Open access
Semantic Scholar
Abstract 2667: Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation
I. Waizenegger, Hengyu Lu, C. Thamer, F. Savarese +11 more
2022Cancer Research11 citations
Semantic Scholar
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Michael White, C. Vellano, M. Andrews, R. Witt +16 more
2022Journal of Clinical Oncology10 citations
Semantic Scholar
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma
Michael G. White, Robert Szczepaniak Sloane, R. Witt, A. Reuben +28 more
2021Oncoimmunology10 citations Open access
Semantic Scholar
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
C. Vellano, Michael G. White, M. Andrews, M. Chelvanambi +61 more
2023Nature7 citations Open access
Semantic Scholar
Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL
Ze Tian, Chunhua Shi, Guojun Yang, Jason K. Allen +16 more
2023Leukemia7 citations Open access
Semantic Scholar
Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set.
S. Schmidt, N. Akhave, R. Knightly, A. Reuben +30 more
2022JCO Clinical Cancer Informatics7 citations Open access
Semantic Scholar
Abstract 1271:In vitroandin vivocharacterization of BI 1823911 - a novel KRASG12Cselective small molecule inhibitor
F. Savarese, A. Gollner, D. Rudolph, Jesse J. Lipp +25 more
2021Experimental and Molecular Therapeutics7 citations
Semantic Scholar
Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
P. Pilié, V. Giuliani, Wei-Lien Wang, D. McGrail +47 more
2024Clinical Cancer Research6 citations Open access
Semantic Scholar
Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer
K. Mahadevan, A. S. Maldonado, Bing-Rui Li, Aaron A. Bickert +12 more
2025bioRxiv5 citations Open access
Semantic Scholar
Clonal dominance defines metastatic dissemination in pancreatic cancer
I-Lin Ho, Chieh-Yuan Li, Fuchenchu Wang, Li Zhao +37 more
2024Science Advances5 citations Open access
Semantic Scholar
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer
Peter Jung, Stefan P. Glaser, Jing Han, Alexandra M. Popa +28 more
2024mAbs5 citations Open access
Semantic Scholar
KRAS Inhibition Activates an Actionable CD24 “Don’t Eat Me” Signal in Pancreatic Cancer
Yong-Kun Wei, Ming-Hui Liu, Er-Yen Yen, Jun Yao +26 more
2023bioRxiv5 citations Open access
Semantic Scholar
Clonal dominance defines metastatic dissemination in pancreatic cancer
I-Lin Ho, Chieh-Yuan Li, Fuchenchu Wang, Li Zhao +24 more
2022Leading Edge of Cancer Research Symposium: Poster Session5 citations Open access
Semantic Scholar
CREBBP/EP300 mutation is associated with poor outcome in HNSCC and targetable with synthetic cytotoxicity.
Manish Kumar, D. Molkentine, J. Molkentine, K. Bridges +15 more
20205 citations
Semantic Scholar
Abstract A085: BI KRASmulti, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in preclinical models and validates wild-type amplified KRAS as a therapeutic target
Antonio Tedeschi, Lorenz Herdeis, Valeria Santoro, F. Savarese +23 more
2023Molecular Cancer Therapeutics4 citations
Semantic Scholar
CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRASG12D inhibition in pancreatic ductal adenocarcinoma
K. McAndrews, K. Mahadevan, Bing-Rui Li, Amari M. Sockwell +25 more
2025bioRxiv3 citations Open access
Semantic Scholar
DPY30 Is an Epigenetic Decoupler Linking Replication Stress to Immunoediting in Pancreatic Cancer
F. Citron, L. Cecchetto, Elisabetta Granato, I-Lin Ho +39 more
2026Cancer Research2 citations Open access
Semantic Scholar
CDK8 remodels the tumor microenvironment and promotes resistance to KRASG12D inhibitors and daraxonrasib in PDAC
K. McAndrews, K. Mahadevan, Bing-Rui Li, Anaïs M Comptdaer +28 more
2026EMBO Journal2 citations Open access
Semantic Scholar
Evolutionary fingerprints of EMT in pancreatic cancers
L. Perelli, Li Zhang, Sarah Mangiameli, Andrew J. C. Russell +26 more
2023bioRxiv2 citations Open access
Semantic Scholar
Abstract 985: BI 905711 selectively induces apoptosis and anti-tumor response in TRAILR2/CDH17- expressing pancreatic cancer models
Jingchao Han, Annette A. Machado, Mikhila Mahendra, J. Daniele +14 more
2021Experimental and Molecular Therapeutics2 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Vellano×18
Invite
C. Vellano — researcher profile on SciRah
A. Carugo×16
Invite
A. Carugo — researcher profile on SciRah
Christopher A. Bristow×15
Invite
Christopher A. Bristow — researcher profile on SciRah
J. Marszalek×15
Invite
J. Marszalek — researcher profile on SciRah

×14

Invite

G. Genovese — researcher profile on SciRah

Invite

N. Feng — researcher profile on SciRah

Andrea Viale×13

Invite

Andrea Viale — researcher profile on SciRah

Invite

G. Draetta — researcher profile on SciRah

Ling-Hua Wang×11

Invite

Ling-Hua Wang — researcher profile on SciRah

Invite

M. Soeung — researcher profile on SciRah

Invite

V. Giuliani — researcher profile on SciRah

Invite

N. Kraut — researcher profile on SciRah